Search

Your search keyword '"Barozzi, Chiara"' showing total 4 results
Start Over Author "Barozzi, Chiara" Topic platelet activation
4 results on '"Barozzi, Chiara"'

1. Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome.

Author

Toso A, De Servi S, Leoncini M, Angiolillo DJ, Calabrò P, Piscione F, Cattaneo M, Maffeo D, Bartorelli A, Palmieri C, De Carlo M, Capodanno D, Genereux P, Bellandi F, Barozzi C, Tomasi L, Della Riva D, and Palmerini T

Subjects
Acute Coronary Syndrome drug therapy, Acute Coronary Syndrome surgery, Aged, Aged, 80 and over, Clopidogrel, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Middle Aged, Ticlopidine analogs & derivatives, Ticlopidine pharmacokinetics, Acute Coronary Syndrome therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Percutaneous Coronary Intervention, Platelet Activation drug effects
Abstract

Statin use is associated with enhanced pharmacodynamic response to clopidogrel in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). However, the impact of statin therapy on clopidogrel response profiles in patients with acute coronary syndrome (ACS) undergoing PCI has not been established and represents the objective of this investigation. On-treatment P2Y 12 platelet reactivity was measured using the vasodilator stimulated phosphoprotein (VASP) phosphorylation assay before PCI, at hospital discharge, and at 1 month after PCI in ACS patients enrolled in the multicenter, prospective GEne polymorphisms, Platelet Reactivity, and Syntax Score (GEPRESS) study (n = 962). High platelet reactivity (HPR) was defined as platelet reactivity index ≥50%. Statins were prescribed at hospital discharge in 87% (n = 835) of patients. All patients were followed for 1 year. The 1-month HPR rate was lower in statin than in non-statin treated patients (39.6 vs 52%, respectively, p = 0.009). This finding was confirmed also among statin-treated patients with high Syntax score (≥15). After adjustment for differences in baseline characteristics, statin use at discharge was independently associated with 1-month HPR rate (odds ratio, 0.58, 95% confidence interval, 0.38-0.89; p = 0.015). In ACS patients undergoing PCI treated with clopidogrel the use of statins at discharge was associated with significantly lower 1-month HPR rates compared with patients not treated with statins.

Published
2017
Full Text
View/download PDF

2. Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.

Author

De Servi S, Crimi G, Calabrò P, Piscione F, Cattaneo M, Maffeo D, Toso A, Bartorelli A, Palmieri C, De Carlo M, Capodanno D, Barozzi C, Tomasi L, Della Riva D, Angiolillo DJ, and Palmerini T

Subjects
Aged, Aged, 80 and over, Angioplasty, Balloon, Coronary methods, Blood Platelets physiology, Clopidogrel, Diabetes Mellitus, Female, Humans, Male, Middle Aged, Ticlopidine analogs & derivatives, Ticlopidine therapeutic use, Treatment Outcome, Acute Coronary Syndrome therapy, Blood Platelets drug effects, Myocardial Infarction therapy, Percutaneous Coronary Intervention methods, Platelet Activation drug effects, Platelet Aggregation Inhibitors therapeutic use
Abstract

Aims: In patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) treated with PCI, high (H) platelet reactivity (PR) significantly affects one-year outcome. The aim of this report was to analyse the relationships between HPR, the SYNTAX score (SS) and one-year major adverse cardiac events (MACE: cardiac death, myocardial infarction, stent thrombosis) according to diabetes mellitus (DM) status in patients included in the GEne Polymorphism, Platelet REactivity, and the Syntax Score (GEPRESS) study., Methods and Results: PR was measured using the vasodilator-stimulated phosphoprotein (VASP) assay at three time points (before PCI, at hospital discharge and at one month after PCI), with HPR defined as >50% PR index in 1,042 patients treated with aspirin and clopidogrel for one year after PCI. Patients with DM and an SS ≥15 had the highest MACE rate between one month and one year, further increased by the presence of HPR (16.4%). On the other hand, among all patients with an SS <15, MACE rates remained low (<3%), irrespective of DM status and PR., Conclusions: Among NSTE-ACS patients treated with PCI, the combination of DM, an SS ≥15 and HPR characterised a cohort with the highest MACE rate from one month to one year. In such high-risk patients, careful clinical monitoring and implementation of secondary prevention measures, including the use of potent P2Y12 inhibitors, are strongly advised.

Published
2016
Full Text
View/download PDF

3. Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome

Author

Francesco Bellandi, Marco Cattaneo, Mario Leoncini, Marco De Carlo, Cataldo Palmieri, Diego Maffeo, Luciana Tomasi, Diego Della Riva, Tullio Palmerini, Davide Capodanno, Paolo Calabrò, Philippe Généreux, Anna Toso, Antonio L. Bartorelli, Dominick J. Angiolillo, Federico Piscione, Chiara Barozzi, Stefano De Servi, Toso, Anna, De Servi, Stefano, Leoncini, Mario, Angiolillo, Dominick J., Calabro', Paolo, Piscione, Federico, Cattaneo, Marco, Maffeo, Diego, Bartorelli, Antonio, Palmieri, Cataldo, De Carlo, Marco, Capodanno, Davide, Genereux, Philippe, Bellandi, Francesco, Barozzi, Chiara, Tomasi, Luciana, Della Riva, Diego, and Palmerini, Tullio

Subjects
medicine.medical_specialty, Acute coronary syndrome, Ticlopidine, Statin, medicine.drug_class, medicine.medical_treatment, High platelet reactivity, 030204 cardiovascular system & hematology, Coronary artery disease, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, P2Y12, Internal medicine, medicine, Humans, cardiovascular diseases, 030212 general & internal medicine, Clopidogrel, Pharmacodynamics, Statins, Aged, Aged, 80 and over, Pharmacodynamic, business.industry, Percutaneous coronary intervention, Hematology, Odds ratio, Middle Aged, Platelet Activation, medicine.disease, Cardiology and Cardiovascular Medicine, Conventional PCI, Cardiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, medicine.drug
Abstract

Statin use is associated with enhanced pharmacodynamic response to clopidogrel in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). However, the impact of statin therapy on clopidogrel response profiles in patients with acute coronary syndrome (ACS) undergoing PCI has not been established and represents the objective of this investigation. On-treatment -P2Y(12) platelet reactivity was measured using the vasodilator stimulated phosphoprotein (VASP) phosphorylation assay before PCI, at hospital discharge, and at 1 month after PCI in ACS patients enrolled in the multicenter, prospective GEne polymorphisms, Platelet Reactivity, and Syntax Score (GEPRESS) study (n = 962). High platelet reactivity (HPR) was defined as platelet reactivity index >= 50%. Statins were prescribed at hospital discharge in 87% (n = 835) of patients. All patients were followed for 1 year. The 1-month HPR rate was lower in statin than in non-statin treated patients (39.6 vs 52%, respectively, p=0.009). This finding was confirmed also among statin-treated patients with high Syntax score (>= 15). After adjustment for differences in baseline characteristics, statin use at discharge was independently associated with 1-month HPR rate (odds ratio, 0.58, 95% confidence interval, 0.38-0.89; p=0.015). In ACS patients undergoing PCI treated with clopidogrel the use of statins at discharge was associated with significantly lower 1-month HPR rates compared with patients not treated with statins.

Published
2017

4. Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention

Author

Davide Capodanno, Paolo Calabrò, Dominick J. Angiolillo, Tullio Palmerini, Anna Toso, Marco Cattaneo, Federico Piscione, Marco De Carlo, Stefano De Servi, Chiara Barozzi, Diego Della Riva, Cataldo Palmieri, Diego Maffeo, Antonio L. Bartorelli, Gabriele Crimi, Luciana Tomasi, De Servi, Stefano, Crimi, Gabriele, Calabro', Paolo, Piscione, Federico, Cattaneo, Marco, Maffeo, Diego, Toso, Anna, Bartorelli, Antonio, Palmieri, Cataldo, De Carlo, Marco, Capodanno, Davide, Barozzi, Chiara, Tomasi, Luciana, Riva, Diego Della, Angiolillo, Dominick J., and Palmerini, Tullio

Subjects
Blood Platelets, Male, Acute coronary syndrome, medicine.medical_specialty, Ticlopidine, medicine.medical_treatment, Myocardial Infarction, 030204 cardiovascular system & hematology, Acute coronary syndromes, Diabete, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Internal medicine, Clopidogrel, Diabetes, SYNTAX score, Cardiology and Cardiovascular Medicine, Diabetes Mellitus, medicine, Humans, 030212 general & internal medicine, Myocardial infarction, Platelet activation, cardiovascular diseases, Angioplasty, Balloon, Coronary, Aged, Aged, 80 and over, business.industry, Percutaneous coronary intervention, Middle Aged, Platelet Activation, medicine.disease, Treatment Outcome, Conventional PCI, Cardiology, Platelet aggregation inhibitor, Female, business, Platelet Aggregation Inhibitors, Mace, medicine.drug
Abstract

Aims: In patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) treated with PCI, high (H) platelet reactivity (PR) significantly affects one-year outcome. The aim of this report was to analyse the relationships between HPR, the SYNTAX score (SS) and one-year major adverse cardiac events (MACE: cardiac death, myocardial infarction, stent thrombosis) according to diabetes mellitus (DM) status in patients included in the GEne Polymorphism, Platelet REactivity, and the Syntax Score (GEPRESS) study.Methods and results: PR was measured using the vasodilator-stimulated phosphoprotein (VASP) assay at three time points (before PCI, at hospital discharge and at one month after PCI), with HPR defined as >50% PR index in 1,042 patients treated with aspirin and clopidogrel for one year after PCI. Patients with DM and an SS >= 15 had the highest MACE rate between one month and one year, further increased by the presence of HPR (16.4%). On the other hand, among all patients with an SS = 15 and HPR characterised a cohort with the highest MACE rate from one month to one year. In such high-risk patients, careful clinical monitoring and implementation of secondary prevention measures, including the use of potent P2Y(12) inhibitors, are strongly advised.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results